Format

Send to

Choose Destination
Tumour Biol. 2017 Feb;39(2):1010428317691417. doi: 10.1177/1010428317691417.

Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma.

Zhang H1,2, Liu Y1, Xie H3,4, Fu Q1, Liu Z1, Zhu Y3,4, Xu L5, Zhang W6, Yang Y7, Xu J1.

Author information

1
1 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
2
2 Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Jiangsu, China.
3
3 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
4
4 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
5
5 Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
6
6 Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
7
7 Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.

Abstract

Beta-1,4-galactosyltransferase II is found to be associated with the alterations of tumor-related glycosylation. However, the clinical significance of beta-1,4-galactosyltransferase II in non-metastatic clear-cell renal cell carcinoma has not been reported up to now. Herein, our researches suggested that the expression level of beta-1,4-galactosyltransferase II was first found to be positively associated with tumor size, Fuhrman grade, lymphovascular invasion, rhabdoid differentiation, tumor necrosis and poor overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma, both in training set and validation set. Moreover, beta-1,4-galactosyltransferase II expression was identified as an independent adverse prognosticator for overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma. Ultimately, prognostic accuracy of the nomogram integrating beta-1,4-galactosyltransferase II with other independent prognostic parameters was dramatically improved for overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma. Taken together, beta-1,4-galactosyltransferase II is a potential independent adverse prognostic factor for postoperative recurrence and survival, which could be developed as a useful biomarker for non-metastatic clear-cell renal cell carcinoma by a series of further independent and retrospective studies, so as to help the postsurgical management of clear-cell renal cell carcinoma patients.

KEYWORDS:

Beta-1,4-galactosyltransferase II; clear-cell renal cell carcinoma; overall survival; prognostic biomarker; recurrence-free survival

PMID:
28231735
DOI:
10.1177/1010428317691417
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center